Hemin Treatment Abrogates Monocrotaline-Induced Pulmonary Hypertension

By  

Medicinal Chemistry, Vol. 4, Iss. 6, 2008-11 ,pp. : 572-576

Bentham Science Publishers

Access to resources Recommend Favorite

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

By Rakotoniaina Zo   Guerard Pascal   Lirussi Frederic   Goirand Françoise   Rochette Luc   Dumas Monique   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 374, Iss. 3, 2006-12 ,pp. : 195-206

Springer Publishing Company

Access to resources Recommend Favorite

LUNG INJURY FROM INTRATRACHEAL AND INHALATION EXPOSURES TO RESIDUAL OIL FLY ASH IN A RAT MODEL OF MONOCROTALINE-INDUCED PULMONARY HYPERTENSION

By Kodavanti Urmila P.   Jackson Mette C.   Ledbetter Allen D.   Richards Judy R.   Gardner Sarah Y.   Watkinson William P.   Campen Matthew J.   Costa Daniel L.  

Journal of Toxicology and Environmental Health, Vol. 57, Iss. 8, 1999-08 ,pp. : 543-563

Taylor & Francis Ltd

Access to resources Recommend Favorite

Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat

By Rakotoniaina Zo  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 378, Iss. 3, 2008-09 ,pp. : 241-251

Springer Publishing Company

Access to resources Recommend Favorite

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

By Guerard Pascal   Rakotoniaina Zo   Goirand Françoise   Rochette Luc   Dumas Monique   Lirussi Frederic   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 373, Iss. 6, 2006-09 ,pp. : 401-414

Springer Publishing Company

Access to resources Recommend Favorite